Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. 278, Tmc
2. Hcl, Rilpivirine
3. Hydrochloride, Rilpivirine
4. R278474
5. Rilpivirine Hcl
6. Rilpivirine Hydrochloride
7. Tmc 278
8. Tmc-278
9. Tmc278
1. 500287-72-9
2. Tmc278
3. Edurant
4. Rilpivirine Free Base
5. R278474
6. Tmc 278
7. Tmc-278
8. R 278474
9. (e)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile
10. (e)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile
11. 4-{[4-({4-[(e)-2-cyanoethenyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
12. 4-{[4-({4-[(e)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
13. Chebi:68606
14. Fi96a8x663
15. 500287-72-9 (free Base)
16. 4-[[4-[[4-[(e)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
17. Db08864
18. R-278474
19. Rilpivirine [inn]
20. Rilpivirine [usan:inn]
21. Rilpivirina
22. Unii-fi96a8x663
23. Hsdb 8153
24. Edurant(tm)
25. 4-((4-((4-((1e)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
26. 4-[[4-[[4-[(1e)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
27. T27
28. Rilpivirine [mi]
29. Rilpivirine [jan]
30. Rilpivirine [usan]
31. Rilpivirine [vandf]
32. Rilpivirine [mart.]
33. Rilpivirine [who-dd]
34. Schembl384696
35. Schembl385113
36. Rilpivirine (jan/usan/inn)
37. Chembl175691
38. Gtpl11387
39. Dtxsid10198189
40. Ex-a245
41. Rilpivirine [orange Book]
42. Bdbm222178
43. Bcp03563
44. Zinc1554274
45. Cabenuva Component Rilpivirine
46. Mfcd11046372
47. S7303
48. Stl484047
49. Akos015901680
50. Bcp9000016
51. Ccg-268241
52. Cs-0440
53. Ke-0036
54. R278474;tmc278
55. 4-[[4-[4-[(e)-2-cyanovinyl]-2,6-dimethyl-anilino]pyrimidin-2-yl]amino]benzonitrile
56. Rilpivirine Component Of Cabenuva
57. Ncgc00319175-03
58. Ncgc00319175-08
59. Rilpivirine(r 278474, Tmc 278)
60. Ac-30619
61. Hy-10574
62. Bcp0726000192
63. Sw220232-1
64. D09720
65. A827939
66. Q421547
67. W-202888
68. 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]pyrimidine-2-yl]amino]benzonitrile
69. 4-[[4-[4-[(e)-2-cyanoethenyl]-2,6-dimethylanilino]-2-pyrimidinyl]amino]benzonitrile
70. 4-{4-[4-((e)-2-cyano-vinyl)-2,6-dimethyl-phenylamino]-pyrimidin-2-ylamino}-benzonitrile
71. (e)-3-{4-[2-(p-cyanophenylamino)-4-pyrimidinylamino]-3,5-xylyl}acrylonitrile; 4-[[4-[[4-[(1e)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
72. 4-((4-((4-((1e)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile
73. 4-[[4-[[4-[(e)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzenecarbonitrile
74. Benzonitrile, 4-((4-((4-((1e)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- Pyrimidinyl)amino)-
75. Benzonitrile, 4-((4-((4-((1e)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)-
Molecular Weight | 366.4 g/mol |
---|---|
Molecular Formula | C22H18N6 |
XLogP3 | 4.5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 366.15929460 g/mol |
Monoisotopic Mass | 366.15929460 g/mol |
Topological Polar Surface Area | 97.4 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 607 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Edurant |
PubMed Health | Rilpivirine (By mouth) |
Drug Classes | Antiretroviral Agent |
Active Ingredient | Rilpivirine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 25mg base |
Market Status | Prescription |
Company | Janssen Prods |
2 of 2 | |
---|---|
Drug Name | Edurant |
PubMed Health | Rilpivirine (By mouth) |
Drug Classes | Antiretroviral Agent |
Active Ingredient | Rilpivirine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 25mg base |
Market Status | Prescription |
Company | Janssen Prods |
HIV Reverse Transcriptase/antagonists & inhibitors
National Library of Medicine's Medical Subject Headings. Rilpivirine. Online file (MeSH, 2014). Available from, as of November 19, 2013: https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html
Due to ongoing neuropsychiatric adverse events in some efavirenz (EFV)-treated patients, a switch to an alternative non-nucleoside reverse transcriptase inhibitor may be considered. Rilpivirine (RPV) has been coformulated as a single-tablet regimen (STR) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), and the components have demonstrated noninferior efficacy to EFV+FTC/TDF, good tolerability profile, and high adherence. After discontinuation, EFV has an extended inductive effect on cytochrome P450 (CYP) 3A4 that, after switching, may reduce RPV exposures and adversely impact clinical outcomes. This study examines the clinical implications of reduced RPV exposures with concomitant FTC/TDF and declining EFV exposures when patients, intolerant to EFV, switch from EFV/FTC/TDF to RPV/FTC/TDF. This 48-week, phase 2b, open-label, multicenter study evaluated the efficacy and safety of switching from EFV/FTC/TDF (>/= 3 months duration) to RPV/FTC/TDF. Virologic suppression (HIV-1 RNA <50 copies/mL), safety, and EFV and RPV pharmacokinetics were assessed. At weeks 12 and 24, all 49 dosed subjects remained suppressed on RPV/FTC/TDF. At week 48, 46 (93.9%) subjects remained suppressed and virologic failure occurred in 2/49 (4.1%) subjects with no emergence of resistance. EFV concentrations were above the 90th percentile for inhibitory concentration (IC90) for several weeks after EFV discontinuation, and RPV exposures were in the range observed in phase 3 studies by approximately 2 weeks post switch. No subjects discontinued the study due to an adverse event. Switching from EFV/FTC/TDF to RPV/FTC/ TDF was a safe, efficacious option for virologically suppressed HIV-infected patients with EFV intolerance wishing to remain on an STR.
PMID:24144898 Mills AM et al; HIV Clin Trials 14 (5): 216-23 (2013)
Adverse effects of moderate or severe intensity and reported in 2% or more of patients receiving rilpivirine include depressive disorders, insomnia, headache, and rash. Increased serum AST and/or ALT concentrations (more than 2.5 times the upper limit of normal (ULN) were reported in 3-4% of patients receiving rilpivirine.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 680
Rilpivirine should be used with caution and with increased monitoring for adverse effects in patients with severe renal impairment or end-stage renal disease since concentrations of the drug may be increased due to alterations in absorption, distribution, or metabolism.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 680
Rilpivirine and the fixed combination containing rilpivirine, emtricitabine, and tenofovir (Complera) have not been studied in patients with severe hepatic impairment (Child-Pugh class C).
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 680
Experience in those 65 years of age and older is insufficient to determine whether they respond differently than younger adults. Dosage should be selected with caution because of age-related decreases in hepatic and/or renal function and potential for concomitant disease and drug therapy.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 680
For more Drug Warnings (Complete) data for Rilpivirine (13 total), please visit the HSDB record page.
Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA 100,000 copies/mL and CD4+ cell count >200 cells/mm3. The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.
FDA Label
Edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV1) infection in antiretroviral treatmentnave patients 12 years of age and older with a viral load 100,000 HIV1 RNA copies/ml.
As with other antiretroviral medicinal products, genotypic resistance testing should guide the use of Edurant.
Treatment of human immunodeficiency virus (HIV-1) infection
Rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor that inhibits the replication of HIV-1. It has a long duration of action as the oral tablet is given daily and the intramuscular suspension is given monthly. Patients should be counselled regarding the risk of hypersensitivity reactions, hepatotoxicity, depressive disorders, and the redistribution or accumulation of body fat.
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
J05AG05
J05AG05
J05AG05
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AG - Non-nucleoside reverse transcriptase inhibitors
J05AG05 - Rilpivirine
Absorption
Rilpivirine has a Tmax of 3-4 hours and has a mean AUC of 2235 851 ng\*h/mL. A 25mg dose reaches a Cmax of 247 ng/mL in healthy subjects and 138.6 ng/mL in patients with HIV-1.
Route of Elimination
Rilpivirine is 85% eliminated in the feces and 6.1% eliminated in the urine. 25% of a dose is recovered in the feces as the unchanged parent drug, while <1% of a dose is recovered in the urine as the unchanged parent drug.
Volume of Distribution
In HIV-1 patients, the apparent volume of distribution in the central compartment was 152-173 L.
Clearance
In HIV-1 patients, the apparent total clearance is estimated to be 6.89-8.66 L/h.
After a single oral dose, an average of 85% of the dose is eliminated in feces (75% as metabolites) and 6% is eliminated in urine (only trace amounts as unchanged rilpivirine).
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 681
It is not known whether rilpivirine is distributed into human milk; however, the drug is distributed into milk in rats.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 680
Rilpivirine is predominantly metabolized by CYP3A4 and CYP3A5 to the hydroxylated metabolites M1, M2, M3, and M4. UGT1A1 glucuronidates the M2 metabolite to form M6, UGT1A4 glucuronidates rilpivirine to form M5, and an unknown UGT glucuronidates the M4 metabolite to form M7.
Rilpivirine is metabolized by the cytochrome P-450 (CYP) isoenzyme 3A.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 680
Rilpivirine has a terminal half-life of 34-55 hours.
The terminal elimination half-life of rilpivirine is approximately 50 hours.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 681
Rilpivirine is a non-competitive NNRTI that binds to reverse transcriptase. Its binding results in the blockage of RNA and DNA- dependent DNA polymerase activities, like HIV-1 replication. It does not present activity against human DNA polymerases , and . Rilpivirine's flexible structure around the aromatic rings allows the adaptation to changes in the non-nucleoside RT binding pocket, reducing the likelihood of viral mutations conferring resistance.
Rilpivirine, a diarylpyrimidine nonnucleoside reverse transcriptase inhibitor (NNRTI), inhibits replication of human immunodeficiency virus type 1 (HIV-1) by interfering with viral RNA- and DNA-directed polymerase activities of reverse transcriptase. Diarylpyrimidine NNRTIs (e.g., rilpivirine, etravirine) are capable of adapting to mutations in HIV-1 reverse transcriptase because of structural flexibility that allows for binding to the allosteric NNRTI binding pocket in a variety of conformations. Unlike other currently available NNRTIs, rilpivirine contains a cyanovinyl group that contributes to potency and maintains the drug's binding ability, despite the emergence of some resistance mutations.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 681
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
4-[(4-Hydroxy-2-pyrimidinyl)amino]benzonitrile
CAS Number : 189956-45-4
End Use API : Rilpivirine
About The Company : Glenfin Chemicals, a trusted provider of high-quality chemical solutions tailored to meet the diverse needs of industries worldwide. Based in the heart of inno...
CAS Number : 5637-42-3
End Use API : Rilpivirine
About The Company : Ningbo Chemgoo is a R&D-driven company with core technology of organic chemistry, dedicating in technology development and industrialization. We provide interme...
4-[(4-Hydroxy-2-pyrimidinyl)amino]benzonitrile
CAS Number : 189956-45-4
End Use API : Rilpivirine
About The Company : Ningbo Chemgoo is a R&D-driven company with core technology of organic chemistry, dedicating in technology development and industrialization. We provide interme...
4-[(4-Chloro-2-pyrimidinyl)amino]benzonitrile
CAS Number : 244768-32-9
End Use API : Rilpivirine
About The Company : Ningbo Chemgoo is a R&D-driven company with core technology of organic chemistry, dedicating in technology development and industrialization. We provide interme...
4-N[2(4-Hydroxypyrimidinyl)] aminobenzonitrile
CAS Number : 189956-45-4
End Use API : Rilpivirine
About The Company : Syntame is a Pharm- Heatlh technology company jointly sponsored by two PhD from Hong Kong Polytechnic University & Zhejiang University. We always focus on the m...
(E)-3-(4-Amino-3,5-dimethyl phenyl) acrylonitrile ...
CAS Number : CAS-661489-23-2
End Use API : Rilpivirine
About The Company : OctaneX Labs is a leading intermediates and Active Pharmaceutical Ingredients (API) manufacturing company specializing in the development of innovative processe...
CAS Number : CAS-4102-53-8
End Use API : Rilpivirine
About The Company : OctaneX Labs is a leading intermediates and Active Pharmaceutical Ingredients (API) manufacturing company specializing in the development of innovative processe...
CAS Number : 24596-19-8
End Use API : Rilpivirine
About The Company : OctaneX Labs is a leading intermediates and Active Pharmaceutical Ingredients (API) manufacturing company specializing in the development of innovative processe...
4-Iodo-2, 6-Dimethyl-Benzeneamine
CAS Number : CAS-4102-53-8
End Use API : Rilpivirine
About The Company : We are Rampex Labs, a fully cGMP compliant pharmaceutical intermediates plant located in the outskirts of Hyderabad, India. Our company was founded in 2004 with...
4-[(1, 4-DIHYDRO-4-OXO-2-PYRIMIDINYL)AMINO]BENZONI...
CAS Number : 189956-45-4
End Use API : Rilpivirine
About The Company : SMS Lifesciences is a global player in APIs/Intermediates manufacturing having a strong research and manufacturing team supported by state of the art facilities...
Global Sales Information
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 686
2019 Revenue in Millions : 507
Growth (%) : 35
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 1,672
2019 Revenue in Millions : 1,655
Growth (%) : 1
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 269
2019 Revenue in Millions : 406
Growth (%) : -34
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 964
2019 Revenue in Millions : 861
Growth (%) : 12
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 994
2020 Revenue in Millions : 964
Growth (%) : 3
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 258
2020 Revenue in Millions : 269
Growth (%) : -4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 700
2020 Revenue in Millions : 678
Growth (%) : 4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 51
2020 Revenue in Millions : 0
Growth (%) : New Launch in 2021
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 1,568
2020 Revenue in Millions : 1,672
Growth (%) : -6
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 1,008
2021 Revenue in Millions : 994
Growth (%) : 1
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-06-30
US Patent Number : 11389447
Drug Substance Claim :
Drug Product Claim :
Application Number : 212888
Patent Use Code : U-3405
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-30
Patent Expiration Date : 2025-04-21
US Patent Number : 7125879
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212888
Patent Use Code : U-3348
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-04-21
Patent Expiration Date : 2026-04-28
US Patent Number : 8410103
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212888
Patent Use Code : U-3348
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-04-28
Patent Expiration Date : 2031-09-15
US Patent Number : 12138264
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212888
Patent Use Code : U-3348
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-09-15
Patent Expiration Date : 2026-04-28
US Patent Number : 8410103
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212888
Patent Use Code : U-3348
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-04-28
Patent Expiration Date : 2026-04-28
US Patent Number : 10927129
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212888
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-04-28
Patent Expiration Date : 2031-09-15
US Patent Number : 11224597
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212888
Patent Use Code : U-3348
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-09-15
Patent Expiration Date : 2031-09-15
US Patent Number : 12138264
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212888
Patent Use Code : U-3348
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-09-15
Patent Expiration Date : 2026-04-28
US Patent Number : 10927129
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212888
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-04-28
Patent Expiration Date : 2025-04-21
US Patent Number : 7125879
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212888
Patent Use Code : U-3348
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-04-21
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Rilpivirine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rilpivirine, including repackagers and relabelers. The FDA regulates Rilpivirine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rilpivirine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rilpivirine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rilpivirine supplier is an individual or a company that provides Rilpivirine active pharmaceutical ingredient (API) or Rilpivirine finished formulations upon request. The Rilpivirine suppliers may include Rilpivirine API manufacturers, exporters, distributors and traders.
click here to find a list of Rilpivirine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rilpivirine DMF (Drug Master File) is a document detailing the whole manufacturing process of Rilpivirine active pharmaceutical ingredient (API) in detail. Different forms of Rilpivirine DMFs exist exist since differing nations have different regulations, such as Rilpivirine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rilpivirine DMF submitted to regulatory agencies in the US is known as a USDMF. Rilpivirine USDMF includes data on Rilpivirine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rilpivirine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rilpivirine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rilpivirine Drug Master File in Korea (Rilpivirine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rilpivirine. The MFDS reviews the Rilpivirine KDMF as part of the drug registration process and uses the information provided in the Rilpivirine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rilpivirine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rilpivirine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rilpivirine suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rilpivirine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rilpivirine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rilpivirine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rilpivirine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rilpivirine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rilpivirine suppliers with NDC on PharmaCompass.
Rilpivirine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rilpivirine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rilpivirine GMP manufacturer or Rilpivirine GMP API supplier for your needs.
A Rilpivirine CoA (Certificate of Analysis) is a formal document that attests to Rilpivirine's compliance with Rilpivirine specifications and serves as a tool for batch-level quality control.
Rilpivirine CoA mostly includes findings from lab analyses of a specific batch. For each Rilpivirine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rilpivirine may be tested according to a variety of international standards, such as European Pharmacopoeia (Rilpivirine EP), Rilpivirine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rilpivirine USP).
LOOKING FOR A SUPPLIER?